Brief: Bioinvent Gets IND Approval For Phase I/IIa Trial Of Anti-TNFR2 Antibody BI-1808

BioInvent International AB

07/04/2021 07:38

April 7 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT RECEIVES IND APPROVAL FOR PHASE I/IIA TRIAL OF
ANTI-TNFR2 ANTIBODY BI-1808
    * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED
INVESTIGATIONAL NEW DRUG (IND) FOR PHASE I/IIA CLINICAL STUDY OF
IMMUNO-MODULATORY ANTI-TNFR2 ANTIBODY BI-1808

Source text for Eikon:  ID:nWkrbxnSSd 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))